Clinical Trials
33 trialsNCT03419234 2026-04-01
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT02703623 2026-03-06
Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02522715 2026-02-24
Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer
OHSU Knight Cancer Institute
Phase 1/2 Active not recruiting
NCT06470243 2026-01-22
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
SWOG Cancer Research Network
Phase 3 Recruiting
NCT04592237 2025-12-23
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01420250 2025-05-15
Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer
Thomas Jefferson University
Phase 1 Completed
NCT01437488 2025-05-04
Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
Thomas Jefferson University
Phase 2 Completed
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT02961257 2022-05-12
CABASTY
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Phase 3 Completed
NCT01505868 2021-07-30
Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02844582 2021-01-25
Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
University of California, Davis
Phase 2 Terminated
NCT04622761 2021-01-05
CHROME
The Clatterbridge Cancer Centre NHS Foundation Trust
Phase 2 Unknown
NCT01308567 2019-06-05
FIRSTANA
Sanofi
Phase 3 Completed
NCT01668459 2018-12-04
CabB1
University Hospital Birmingham NHS Foundation Trust
Phase 2/3 Completed
NCT02166658 2018-01-23
CaBaMet
AIO-Studien-gGmbH
Phase 2 Terminated
NCT01718353 2017-11-20
TAXYNERGY
Sanofi
Phase 2 Completed
NCT01693549 2017-08-01
Study of Cabazitaxel in Patients With Metastatic Breast Cancer Previously Treated With Taxanes
Hellenic Cooperative Oncology Group
Phase 2 Completed
NCT01594918 2017-07-21
Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer
University of California, San Francisco
Phase 1 Completed
NCT01934894 2017-07-02
Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT01308580 2017-04-17
PROSELICA
Sanofi
Phase 3 Completed
NCT01751308 2016-08-12
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Sanofi
Phase 1/2 Completed
NCT01649635 2016-07-06
PROSPECTA
Sanofi
Phase 4 Completed
NCT01140607 2015-07-21
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Sanofi
Phase 1 Completed
NCT01500720 2015-04-13
Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer
Sanofi
Phase 2 Completed
NCT01324583 2015-01-07
Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer
Sanofi
Phase 1 Completed
NCT01469338 2014-11-24
Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel
University of Southern California
Phase 2 Terminated
NCT01576029 2013-12-24
SWITCH
Sanofi
Phase 2 Completed
NCT01750866 2013-10-16
Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer
Case Comprehensive Cancer Center
Phase 2 Withdrawn
NCT01001221 2013-09-11
Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor
Sanofi
Phase 1/2 Terminated
NCT00925743 2013-05-16
A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer
Sanofi
Phase 1 Completed
NCT01755390 2012-12-24
A Dose Finding Study of XRP6258 in Patients With Advanced Solid Tumors
Sanofi
Phase 1 Completed
NCT01087021 2011-12-16
QT-Cab
Sanofi
Phase 1 Completed
NCT00417079 2011-03-10
TROPIC
Sanofi
Phase 3 Completed